2024-03-18T14:26:13-05:00 2023-10-31 410746749 CLIFTONLARSONALLEN LLP 420 SOUTH ORANGE AVENUE SUITE 900 ORLANDO FL 32801 990 2022-11-01 363719712 THE KIDNEY CANCER ASSOCIATION KIDN 8008509132 PO BOX 676226 DALLAS TX 75267 GRETCHEN E VAUGHAN PRESIDENT & CEO 8008509132 2024-03-12 1 GRETCHEN VAUGHAN 999009999 0 TINA HENTON P00630282 4078021200 2024-03-11 3 AAL1 IAL1 2022 2023-04-26 12:10:37Z X GRETCHEN E VAUGHAN PO BOX 676226 DALLAS TX 75267 15396636 0 X WWW.KIDNEYCANCER.ORG X 1990 IL A GLOBAL COMMUNITY DEDICATED TO SERVING AND EMPOWERING PATIENTS, AND LEADING CHANGE THROUGH ADVOCACY, RESEARCH, AND EDUCATION. 16 16 19 111 0 0 2818520 2903367 160355 201993 3404208 -824975 7623 99254 6390706 2379639 556083 428470 0 0 2024780 2398212 0 0 402676 1938341 1914527 4519204 4741209 1871502 -2361570 23316300 23797390 2039759 2468132 21276541 21329258 THE KIDNEY CANCER ASSOCIATION IS A GLOBAL COMMUNITY DEDICATED TO SERVING AND EMPOWERING PATIENTS, AND LEADING CHANGE THROUGH ADVOCACY, RESEARCH, AND EDUCATION IN ORDER TO BE THE UNIVERSAL LEADER IN FINDING THE CURE FOR KIDNEY CANCER. 0 0 1526187 EDUCATION - THE KIDNEY CANCER ASSOCIATION PROVIDES OPPORTUNITIES FOR PHYSICIANS, RESEARCHERS, ACADEMICS, AND INDUSTRY PROFESSIONALS FROM ACROSS THE GLOBE TO COME TOGETHER AND EXCHANGE IDEAS THAT WILL DIRECT THE FUTURE OF KIDNEY CANCER RESEARCH AND TREATMENT IN THE ULTIMATE PURSUIT OF A CURE. THE PRIMARY OPPORTUNITIES ARE DURING THE TWO ANNUAL SYMPOSIA, IKCS NORTH AMERICA AND IKCS EUROPE, HELD BOTH IN PERSON. IKCS MEETINGS PROMOTE LEARNING, NETWORKING, AND UNPARALLELED OPPORTUNITIES FOR MENTORSHIP AND COLLABORATION. 1332036 15970 200614 PATIENT SUPPORT AND ADVOCACY - THE KIDNEY CANCER ASSOCIATION SEEKS TO BE A SOURCE OF EDUCATION AND RESOURCES FOR PATIENTS, CAREGIVERS, AND ANYONE IMPACTED BY KIDNEY CANCER. THE KCA PROVIDES PATIENT RESOURCES FOR EACH STAGE OF THE KIDNEY CANCER JOURNEY INCLUDING OUR JUST DIAGNOSED TOOLKIT, PATIENT NAVIGATOR PROGRAM, VIRTUAL PATIENT SYMPOSIUM, KCA CONNECT, PATIENT ASSISTANCE FUND, AND EDUCATIONAL RESOURCES INCLUDING INFORMATION ON TREATMENTS, DRUGS, CLINICAL TRIALS, AND CAREGIVING TO NAME A FEW. 700158 412500 RESEARCH - THE KIDNEY CANCER ASSOCIATION IS COMMITTED TO SUPPORTING HEALTHCARE PROFESSIONALS, FOSTERING PROFESSIONAL COLLABORATION, AND FUNDING RESEARCH THAT ADVANCES OUR UNDERSTANDING OF KIDNEY CANCER. THE ORGANIZATION AWARDED GRANTS TO PHYSICIANS AND SCIENTISTS ENGAGED IN RESEARCH TARGETING EARLY DETECTION AND INNOVATIVE TREATMENTS FOR KIDNEY CANCER. 3558381 1 1 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 0 0 0 1 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 10 0 19 1 0 0 0 0 0 0 0 0 0 0 0 0 X 16 16 0 0 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 1 1 0 IL X LARANDA BURKE 8008509132 2777 ALLEN PARKWAY SUITE 424 HOUSTON TX 77019 GRETCHEN VAUGHAN PRESIDENT & CEO 40.00 X 310695 0 54568 KENDALL MONROE CHIEF ADVANCEMENT OFFICER 40.00 X 215906 0 49597 LARANDA BURKE CHIEF FINANCIAL & OPERATING OFFICER 40.00 X 169583 0 33168 ANGELA WASHINGTON DIRCTOR OF OPERATIONS 40.00 X 104640 0 23427 RADHA CHITALE SR. DIRECTOR OF COMMUNICATIONS 40.00 X 104354 0 22346 SALVATORE LA ROSA CHIEF SCIENTIFIC OFFICER 40.00 X 0 0 0 BRADLEY LEIBOVICH MD BOARD CHAIR 1.00 X X 0 0 0 NOAH BUNTMAN BOARD TREASURER 1.00 X X 0 0 0 JOEL STERN SECRETARY 0.50 X X 0 0 0 BRIAN SHUCH MD DIRECTOR 0.50 X 0 0 0 CRAIG DEPRIESTER DIRECTOR 0.50 X 0 0 0 DANIEL GEORGE MC DIRECTOR 0.50 X 0 0 0 DAVID PERRY ESQ DIRECTOR 0.50 X 0 0 0 JAMIE GRAVES DIRECTOR 0.50 X 0 0 0 LAURA WOOD RN DIRECTOR 0.50 X 0 0 0 LAURENCE ALBIGES MD PHD DIRECTOR 0.50 X 0 0 0 MAHUL B AMIN MD DIRECTOR 0.50 X 0 0 0 RONALD BUKOWSKI MD DIRECTOR 0.50 X 0 0 0 RUBEN YBARRA DIRECTOR 0.50 X 0 0 0 RYAN NATZKE DIRECTOR 0.50 X 0 0 0 SHELLEY ROBSON DIRECTOR 0.50 X 0 0 0 TESSA CHURCHILL MD DIRECTOR 0.50 X 0 0 0 905178 0 183106 5 0 1 0 THE FRANCE FOUNDATION 8431 SOLUTIONS CENTER SUITE 100 CHICAGO IL 60677 CONTINUING MEDICAL EDUCATION ACCREDITATI 140136 58 2017 W GRAY STREET SUITE 10 HOUSTON TX 77019 MARKETING SERVICES 134588 EVENT POINT LLC 1311 HASTINGS DR REMERTON GA 31601 EVENT PRODUCTION SERVICES AND EQUIPMENT 133488 3 2903367 7777 2903367 SYMPOSIA REGISTRATIONS 611710 201993 201993 201993 678656 678656 11510640 13014271 -1503631 -1503631 -1503631 1347 2726 -1379 -1379 RETURNED GRANTS 900099 75000 75000 MISCELLANEOUS INCOME 900099 33486 33486 GAIN ON EXCHANGE RATES 900099 -7853 -7853 100633 2379639 200614 0 -724342 412500 412500 15970 15970 981870 679052 162597 140221 1076447 739233 282576 54638 40084 27525 12137 422 153928 103039 40692 10197 145883 99616 35002 11265 19667 19667 21209 21209 60966 60966 354134 254004 12522 87608 104362 61520 906 41936 44114 31363 8827 3924 202079 129938 37233 34908 61680 27756 30069 3855 174284 158883 7367 8034 12032 914 10772 346 2326 1047 1134 145 12908 4376 8120 412 EDUCATION PROGRAMS 738596 738596 PATIENT PROGRAMS 55428 55428 BANK SERVICE CHARGES 24384 12215 12169 STATE REGISTRATION FEES 16780 12419 4361 9578 5406 3768 404 4741209 3558381 780152 402676 55037 52700 535806 1510000 44937 16903 542101 357472 16287 8144 10470 8143 21615757 21195632 512192 656540 23316300 23797390 334330 391505 500000 500000 1205429 1418160 0 158467 2039759 2468132 X 20682281 20737858 594260 591400 21276541 21329258 23316300 23797390 X -2361570 2425599 -11312 X 0 1 X 1 0 X 2596827 770325 2826146 2818520 2903367 11915185 2596827 770325 2826146 2818520 2903367 11915185 2980873 8934312 749616 738200 463048 703006 678656 3332526 82261 1405 251669 7015 100633 442983 15690694 873140 0.56940 0.53050 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER GROSS INCOME - 2018 AMOUNT: $ 82,261. 2019 AMOUNT: $ 1,405. 2020 AMOUNT: $ 251,669. 2021 AMOUNT: $ 9,657. 2022 AMOUNT: $ 108,486. LOSS ON EXCHANGE RATES - 2021 AMOUNT: $ -2,642. 2022 AMOUNT: $ -7,853. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 16678507 36208 1137450 375000 450000 17027165 21581262 172629 -3850384 1225000 16678507 17837624 3743638 21581262 19190328 157296 1510000 17837624 18282601 1707727 800000 19190328 0.99210 0.00790 0.00000 0 0 16287 8144 8143 8143 LEASE LIABILITY - 158467 158467 X 4735686 2425599 -11312 2414287 2321399 60966 -2726 58240 2379639 4682969 0 4682969 60966 -2726 58240 4741209 PART V, LINE 4: THE ASSOCIATION ESTABLISHED A RESERVE TO FUND FUTURE OPERATIONS AND AN ENDOWMENT FUND FOR RESEARCH AND PATIENT SERVICES. IN 2022, THE ASSOCIATION ESTABLISHED AN ENDOWMENT FUND AND RECEIVED CERTAIN GIFTS FROM THE DONOR TO BE MAINTAINED IN PERPETUITY. PART X, LINE 2: THE ASSOCIATION QUALIFIES AS A TAX-EXEMPT ORGANIZATION UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND, THEREFORE, HAS NO PROVISION FOR FEDERAL INCOME TAXES. IT IS ALSO EXEMPT FROM STATE INCOME TAX UNDER THE ILLINOIS CHARITABLE TRUST ACT. THE ASSOCIATION FOLLOWS THE GUIDANCE OF ACCOUNTING STANDARDS CODIFICATION (ASC) 740, ACCOUNTING FOR INCOME TAXES, RELATED TO UNCERTAINTIES IN INCOME TAXES, WHICH PRESCRIBES A THRESHOLD OF MORE LIKELY THAN NOT FOR RECOGNITION AND DERECOGNITION OF TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. THERE ARE NO SUCH UNCERTAIN TAX POSITIONS FOR THE ASSOCIATION FOR THE YEARS ENDED OCTOBER 31, 2023 AND 2022. PART XI, LINE 2D - OTHER ADJUSTMENTS: CHANGE IN VALUE - SPLIT INTEREST AGREEMENT -11,312. PART XI, LINE 4B - OTHER ADJUSTMENTS: COST OF GOODS SOLD -2,726. PART XII, LINE 4B - OTHER ADJUSTMENTS: COST OF GOODS SOLD -2,726. 0 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES INTERNATIONAL KIDNEY CANCER SYMPOSIUM 245754 0 0 0 0 0 0 245754 0 245754 0 0 0 0 0 0 PART III ACCOUNTING METHOD: 1 REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 6500 GILMAN DRIVE LA JOLLA CA 92093 956006144 501(C)3 112500 0 N/A N/A RESEARCH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES 1125 MURPHY HALL LOS ANGELES CA 90995 956006143 501(C)3 75000 0 N/A N/A RESEARCH THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER PO BOX 4390 HOUSTON TX 77210 746001118 UNIVERSITY OF TEXAS 75000 0 N/A N/A RESEARCH DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVE BP418 BOSTON MA 02215 042263040 501(C)3 75000 0 N/A N/A RESEARCH MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVE NEW YORK NY 10065 131924236 501(C)3 75000 0 N/A N/A RESEARCH 5 0 PATIENT ASSISTANCE VISA GIFT CARDS 66 15970 0 N/A N/A PART I, LINE 2: THE GRANT REVIEW PROCESS THOROUGHLY VETS GRANT APPLICANTS. IF SELECTED TO RECEIVE A KCA RESEARCH GRANT, THE GRANTEE MUST SIGN A KCA GRANT ACCEPTANCE AGREEMENT TERMS AND CONDITIONS. THIS AGREEMENT REQUIRES THE GRANTEE TO SUBMIT A GRANT PROGRESS REPORT WITH OUTCOMES, POSSIBLE FUTURE RESEARCH DIRECTIONS, REFLECTIVE IMPACT STATEMENT, AND AN ACCOUNTING OF HOW THE GRANT FUNDS WERE USED. THROUGH OUR PATIENT ASSISTANCE FUND, WE HELP KIDNEY CANCER PATIENTS OFFSET COSTS THEY INCUR WHEN GETTING TREATMENT LIKE PARKING, MEALS, ETC. WE SEND THEM A KCA BRANDED VISA GIFT CARD IN EITHER A $50 OR $250 AMOUNT BASED ON THEIR NEED. WE ALSO WORK DIRECTLY WITH TREATMENT FACILITIES TO PROVIDE $25 KCA BRANDED VISA GIFT CARDS TO KIDNEY CANCER PATIENTS WHILE THEY ARE AT THE FACILITY RECEIVING TREATMENT. X X X 0 0 0 0 0 0 0 0 0 GRETCHEN VAUGHAN PRESIDENT & CEO 259215 0 51480 0 0 0 15250 0 39318 0 365263 0 0 0 KENDALL MONROE CHIEF ADVANCEMENT OFFICER 195267 0 20639 0 0 0 10452 0 39145 0 265503 0 0 0 LARANDA BURKE CHIEF FINANCIAL & OPERATING OFFICER 151583 0 18000 0 0 0 7247 0 25921 0 202751 0 0 0 FORM 990, PART VI, SECTION A, LINE 8B THE ORGANIZATION DOES NOT HAVE A COMMITTEE WITH AUTHORITY TO ACT ON BEHALF OF THE GOVERNING BODY. FORM 990, PART VI, SECTION B, LINE 11B THE 990 IS REVIEWED IN DETAIL BY THE CHIEF FINANCIAL AND OPERATING OFFICER AND THE PRESIDENT/CEO BEFORE SIGNING. THE RETURN IS MADE AVAILABLE TO THE FULL BOARD OF DIRECTORS TO REVIEW VIA EMAIL BEFORE IT IS FILED. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION HAS A WRITTEN CONFLICT OF INTEREST POLICY THAT REQUIRES EMPLOYEES AND BOARD MEMBERS TO ANNUALLY DISCLOSE INTERESTS THAT COULD GIVE RISE TO CONFLICTS. AT THE NOVEMBER BOARD MEETING, EVERY BOARD MEMBER IS REQUIRED TO COMPLETE A CONFLICT OF INTEREST QUESTIONNAIRE ACKNOWLEDGING THEY UNDERSTAND THE POLICY AND DISCLOSING ANY CONFLICTS OF INTEREST THEY ARE AWARE OF. THROUGHOUT THE YEAR, SIGNIFICANT CONTRACTS AND TRANSACTIONS ARE REVIEWED BY THE CHIEF FINANCIAL AND OPERATING OFFICER AND THE PRESIDENT/CEO FOR POTENTIAL CONFLICTS. IF AN ACTUAL OR POTENTIAL CONFLICT IS IDENTIFIED, THE ASSOCIATION ACQUIRES AT LEAST TWO OTHER QUOTES TO PRESENT TO THE FINANCE COMMITTEE FOR APPROVAL PRIOR TO RATIFYING WITH THE BOARD OF DIRECTORS. THE CONFLICTED MEMBER IS RECUSED FROM VOTING ON MATTERS IN WHICH THE CONFLICT IS IDENTIFIED. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD CHAIR AND THE NOMINATING AND GOVERNANCE COMMITTEE (NGC) IS RESPONSIBLE FOR ADMINISTERING THE ANNUAL PERFORMANCE EVALUATION OF THE PRESIDENT/CEO. THE NGC REVIEWS COMPENSATION DATA THAT IS AVAILABLE ON SITES LIKE CHARITY NAVIGATOR AND GUIDESTAR AS WELL AS THE 990 RETURNS OF SIMILAR NONPROFIT ORGANIZATIONS. THE NGC MAKES A RECOMMENDATION TO THE BOARD AND THE BOARD VOTES ON THE COMPENSATION OF THE PRESIDENT/CEO. THE PRESIDENT/CEO, CHIEF ADVANCEMENT OFFICER, CHIEF SCIENTIFIC OFFICER, DIRECTOR OF OPERATIONS, AND CHIEF FINANCIAL AND OPERATING OFFICER WORKED TOGETHER TO REVIEW THE MERIT INCREASES AND BONUSES OF THE STAFF. THE FACTORS CONSIDERED IN AWARDING INCREASES WAS PERFORMANCE REVIEW RATING, ACCOMPLISHMENT OF GOALS, LENGTH OF SERVICE, ANY RECENT PROMOTIONS, AND THE APPROVED ANNUAL BUDGET. THE PROCESS DESCRIBED HERE WAS LAST COMPLETED IN 2023. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS BY-LAWS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE GENERAL PUBLIC UPON REQUEST. FORM 990, PART XI, LINE 9: CHANGE IN VALUE - SPLIT INTEREST AGREEMENT -11,312.